Welcome to the News You Might Have Missed, a weekly roundup of psychedelic industry news to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
New Study Shows Positive Results for Compass Pathways’ COMP360
“These independent studies looked at two of the most challenging mental health conditions, where patients are unlikely to receive relief from current available treatments. The results provide promising preliminary evidence that COMP360 psilocybin therapy could help people living with anorexia nervosa and severe treatment-resistant depression and underlines our belief that this needs to be further investigated in larger scale clinical studies.” – Dr Guy Goodwin, Chief Medical Officer, COMPASS Pathways, on the recent results from two studies using the company’s COMP360 compound.
MindBio Therapeutics Completes World’s First Microdosing Trial
MindBio remains the only organization to have successfully obtained government approvals for a doctor to prescribe LSD (lysergic acid diethylamide) to patients to take the drug unsupervised in the community in the same way they would take any other medicine. The Phase 1 clinical trial report and safety data is being analyzed and will be announced shortly.
Optimi Health Granted Amendment To Dealer’s Licence
Optimi’s operational footprint now includes 20,000 square feet of state-of-the-art, technologically advanced aeroponics facilities dedicated to the cultivation of safe, high-quality psychedelic and functional mushrooms. Under the terms of the amendment, the Company is now permitted to possess a quota of up to 5000kg of dried psilocybin mushrooms – the equivalent of 10kg of psilocybin – and 100g of psilocin.
Wesana Plans to Sell Clinics, Focus on Drug Development
Wesana Health has announced its plan for a “strategic review of Wesana’s care delivery division” and that “the Company is reviewing strategic alternatives including, but not limited to, a sale of all the assets under the care delivery division…”
Mydecine closes raise with gross proceeds of $1,693,434.60
The Offering resulted in the issuance of 1,254,396 common shares in the capital of the Company (“Shares”) at a price of $1.35 per Share for aggregate gross proceeds of $1,693,434.60. The distribution of the Shares is qualified by the Prospectus Supplement.
